Arecor Therapeutics plc (FRA:6UI)

Germany flag Germany · Delayed Price · Currency is EUR
0.720
0.00 (0.00%)
Last updated: Dec 4, 2025, 3:29 PM CET
-19.55%
Market Cap 32.00M
Revenue (ttm) 5.90M
Net Income (ttm) -9.45M
Shares Out n/a
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.635
Previous Close 0.720
Day's Range 0.635 - 0.720
52-Week Range 0.484 - 0.895
Beta n/a
RSI 67.24
Earnings Date Dec 24, 2025

About Arecor Therapeutics

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes;... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Employees 44
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6UI
Full Company Profile

Financial Performance

In 2024, Arecor Therapeutics's revenue was 5.05 million, an increase of 10.50% compared to the previous year's 4.57 million. Losses were -10.24 million, 19.7% more than in 2023.

Financial numbers in GBP Financial Statements

News

There is no news available yet.